Details of the Drug

General Information of Drug (ID: DMI7CYZ)

Drug Name

Amiselimod

Synonyms

Amiselimod; 942399-20-4; Amiselimod [INN]; Amiselimod free base; Amiselimod(MT-1303) free base; 942399-20-4 (free base); 358M5150LY; 2-amino-2-(4-(heptyloxy)-3-(trifluoromethyl)phenethyl)propane-1,3-diol; 2-Amino-2-(2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl)propane-1,3-diol; 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol; 2-Amino-2-{2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl}propane-1,3-diol; UNII-358M5150LY; Amiselimod,MT1303; Amiselimod (USAN/INN); AMISELIMOD [USAN]; AMISELIMOD [WHO-DD]; MT-1303 FREE BASE; GTPL9319; SCHEMBL2463680; CHEMBL3707375; JVCPIJKPAKAIIP-UHFFFAOYSA-N; DTXSID301141402; BCP24738; EX-A1427; MT1303; AKOS032971355; Example 1 [US20090137530]; D10905; MT-1303; MT1303; MT 1303; Q27256444; 1,3-PROPANEDIOL, 2-AMINO-2-(2-(4-(HEPTYLOXY)-3-(TRIFLUOROMETHYL)PHENYL)ETHYL)-; 2-Amino-2-[2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl]-1,3-propanediol

Indication

Disease Entry	ICD 11	Status	REF
Ulcerative colitis	DD71	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C19H30F3NO3
Canonical SMILES: CCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F
InChI: InChI=1S/C19H30F3NO3/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3
InChIKey: JVCPIJKPAKAIIP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 16129483
UNII: 358M5150LY
DrugBank ID: DB17074
TTD ID: D2E4CG

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 2 (S1PR2)	TTVSMOH	S1PR2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04857112) A Phase 2, Randomized, Double-Blinded, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC). U.S.National Institutes of Health.
2	Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017 Jan;174(1):15-27.